Vanda Pharmaceuticals (VNDA) Set to Release Earnings on Wednesday

Vanda Pharmaceuticals (NASDAQ:VNDA) will likely be announcing its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect Vanda Pharmaceuticals to announce earnings of ($0.72) per share and revenue of $69.20 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:30 PM ET.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.46). Vanda Pharmaceuticals had a negative return on equity of 49.81% and a negative net margin of 127.41%. The firm had revenue of $50.53 million for the quarter, compared to the consensus estimate of $61.92 million. On average, analysts expect Vanda Pharmaceuticals to post ($3.02) EPS for the current fiscal year and ($0.96) EPS for the next fiscal year.

Vanda Pharmaceuticals Price Performance

Vanda Pharmaceuticals stock opened at $3.94 on Tuesday. The company has a market capitalization of $238.21 million, a price-to-earnings ratio of -0.85 and a beta of 0.69. The company has a current ratio of 1.61, a quick ratio of 1.60 and a debt-to-equity ratio of 0.01. Vanda Pharmaceuticals has a 12 month low of $3.88 and a 12 month high of $9.94. The stock’s 50 day moving average is $4.91 and its 200-day moving average is $6.29.

Analyst Upgrades and Downgrades

VNDA has been the subject of several recent research reports. Zacks Research downgraded Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Thursday, October 15th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a research report on Monday, October 5th. Oppenheimer began coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 price target on the stock. Finally, B. Riley Financial reaffirmed a “buy” rating and set a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a research report on Monday, August 10th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $13.08.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.